Quince Therapeutics, Inc.
QNCX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.03 | 0.01 | -0.27 |
| FCF Yield | -39.75% | -47.19% | -206.88% | -16.83% |
| EV / EBITDA | -1.58 | -1.03 | 0.46 | -3.41 |
| Quality | ||||
| ROIC | -53.42% | -21.71% | -50.84% | -74.96% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.56 | 0.58 | 0.85 | 0.70 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -74.30% | 58.23% | 30.01% | -24.07% |
| Safety | ||||
| Net Debt / EBITDA | -0.15 | 0.22 | 0.88 | 0.76 |
| Interest Coverage | 0.00 | 0.00 | -91.58 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -5,696.75 | -2,304.49 | -1,188.86 | -5,210.80 |